Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
37 NC counties are under alert, including Johnston and Chatham counties.
Closings
1 closing/delay reported.
Just In
At least 1 death in Buncombe County from Helene, western NC official says
Just In
Storm caused deaths in five states, millions to lose power and record rainfall
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
47.32
+0.83 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
29
30
Next >
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
October 24, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
October 22, 2022
Vertex and LNG play Cheniere Energy are setting up bullishly.
Via
Investor's Business Daily
The Top 5 Stocks Cathie Wood Bought and Sold This Week
October 21, 2022
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.
Via
InvestorPlace
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
October 21, 2022
They're both using unique and highly efficient approaches to developing and deploying their medicines.
Via
The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
2 Under-the-Radar Biotech Stocks to Buy in 2022
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
3 Cathie Wood Stocks to Buy and Hold for 10 Years
October 19, 2022
The risks are formidable, but the chances of a massive gain are too much to pass up.
Via
The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
October 18, 2022
These biotech companies have a long ramp of revenue growth ahead.
Via
The Motley Fool
My Best Stocks to Buy Now and Hold Forever
October 14, 2022
These are ideal "forever" stocks.
Via
The Motley Fool
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
October 12, 2022
Vertex already generates billions in revenue -- but there may be more to come.
Via
The Motley Fool
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics
October 11, 2022
Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
October 10, 2022
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023
Via
InvestorPlace
2 Cathie Wood Stocks That Are Beating the Market This Year
October 07, 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Via
The Motley Fool
Vertex Shares Higher On Optimism About CRISPR Partnership
October 05, 2022
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments.
Via
MarketBeat
Exposures
Product Safety
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
October 03, 2022
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash.
Via
Benzinga
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market
October 01, 2022
Vertex flashed a buy signal on positive gene-editing news.
Via
Investor's Business Daily
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022
MaxCyte Inc (NASDAQ: MXCT) has signed a
Via
Benzinga
What Is Going on With Grom Social (GROM) Stock Today?
September 27, 2022
Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media.
Via
InvestorPlace
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today?
September 27, 2022
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today!
Via
InvestorPlace
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
September 27, 2022
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review.
Via
InvestorPlace
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug
September 27, 2022
Crispr and Vertex nailed down the timeline for their blood diseases gene editor.
Via
Investor's Business Daily
Why CRISPR Therapeutics Stock Is Rising Today
September 27, 2022
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S.
Via
Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
September 24, 2022
Eli Lilly leads medical stocks setting up and showing relative strength.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today
September 20, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
No One Told These 3 Stocks It’s a Down Week
September 16, 2022
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Electric Vehicles
Interest Rates
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.